Study of S-1 as Second Line Treatment on Advanced Pancreatic Cancers
NCT01074996
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
92
Enrollment
OTHER
Sponsor class
Conditions
Pancreatic Cancer
Interventions
DRUG:
S-1
DRUG:
S-1 plus Leucovorin
Sponsor
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences